• Save
Upcoming SlideShare
Loading in...5

Like this? Share it with your network



Uploaded on

Final presentation for the Scaife Advanced Student Medical Seminar by Lyndsey Heise

Final presentation for the Scaife Advanced Student Medical Seminar by Lyndsey Heise

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 2

http://www.pearltrees.com 2

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. IbogaineLyndsey HeiseSouthern Illinois UniversitySchool of Medicine
  • 2.  Derived from the Iboga plant bark root Found in Gabon Used by traditional healers to induce “near-death experience”
  • 3.  Ibogaine use in psychotherapy Leo Zeff •American psychologist •In 1960’s, used Ibogaine for “retrospective experience” during therapy
  • 4.  Anti-addictive effects of Ibogaine discovered accidently Howard Lotsof (1943-2010) •Heroin addict •Researcher •Patent holder
  • 5.  An indole alkoloid Structure very similar to serotonin Appears to have a novel mechanism of action NMDA (glutamate) antagonist Agonist at mu- and kappa- opioid receptors Serotonin and dopamine uptake inhibitor Potent non-competitive antagonist at nicotinic receptors
  • 6. Theories behind Ibogaine He and colleagues injected alcoholic rat VTAs directly w/ Ibogaine and observed ↓ alcohol seeking behavior Consistent cocaine or morphine exposure- ↓ GDNF GDNF into VTA leads to ↓ alcohol seeking behavior Ibogaine ↑ expression of GDNF mRNA Anti-GDNF antibodies ↓ effects of Ibogaine He, D., McGough, N., Raindranathan, A., Jeanblanc, J., Logrip, M., Phamluong, K., ….. Ron, Dorit. (2005). Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug Ibogaine against alcohol consumption. Journal of Neuroscience, 25, 619–628.
  • 7. After Ingestion Acute phase (4-8 hours)  Hallucinations (“awakened dream”; EEG shows REM-like patterns)  Ataxia  Nausea/vomiting  Tremors Reflective phase (8-20 hours)  Calmer, acute symptoms largely cease  Often reflect on visions presented in previous phase
  • 8. Safety Concerns Indirectly linked to several sudden deaths Causes arrhythmias Long QT Syndrome Shown to damage Purkinje cells in rat cerebellums Bradycardia Hypotension
  • 9. Legal Status Unscheduled EXCEPT for  US (determined schedule 1 in 1970; only 2 arrests since)  Belgium  Denmark  France  Sweden  Switzerland  Australia
  • 10. Ibogaine Treatment Sites US (shhh!!) Mexico Canada UK Thailand New Zealand Brazil Venezuela Holland And many more….
  • 11. So, how effective is Ibogaine? Difficultto determine since so little research In 1993, the FDA approved a human trial but the doses were subclinical and it was suspended shortly thereafter.
  • 12. Alper/Lotsof Trial (1962-1993) 41 patients; several treated more than once in a short period for a total of 52 treatments 38 of 41 patients had opioid dependency 10 of 41 had other drug or alcohol dependency 25 of 41 patients had complete resolution of opioid withdrawal symptoms in 24 hours 15 (29%) – drug cessation <2 months 15 (29%) – drug cessation 2-6 months 7 (13%) – drug cessation 6 months-1 year 10 (19%) – drug cessation >1 year 5 (10%) – could not be trackedAlper, K., Lotsof, H., Frenken, G., Luciano, D., & Bastiaans, J. (1999). Treatment of acute opioid withdrawal with Ibogaine. The American Journal on Addictions, 8, 234-242.
  • 13. More Studies Anti-addictive effects have been shown in lab animals with drugs, alcohol, nicotine, and even food. Anti-infective properties shown with various viruses, yeast, and even parasites.
  • 14. Why so little clinical research? Many think it will be poorly tolerated because of its fairly severe psychedelic effects. $$$! Little to gain- since it come from natural source, it cannot be patented. Difficult to do double blind study. Dangerous
  • 15. Documentaries Facing the Habit (2007)  Directed by Magnolia Martin I’m Dangerous with Love (2009)  Directed by Michel Nigroponte Ibogaine: Rite of Passage (2004)  Directed by Ben Deloenen Detox or Die (2004)  Directed by David Graham Scott
  • 16. References Hevesi, D. (2010, February 17). Howard Lotsof Dies at 66; Saw Drug Cure in a Plant. The New York Times. Retrieved from http://www.nytimes.com/2010/02/17/us/17lotsof.html. Depoortere, H. (1987). Neocortical rhythmic slow activity during wakefulness and paradoxical sleep in rats. Neuropsychobiology, 18, 160-168. Alper, K., Lotsof, H., & Kaplan, C. (2008). The Ibogaine medical subculture. Journal of Ethnopharmacology, 115, 9-24. Alper, K. (2001). Ibogaine: a review. The Alkaloids, 56, 1- 38.